VERACYTE INC (VCYT) Stock Price, Quote, News and Overview
NASDAQ:VCYT - Nasdaq - US92337F1075 - Common Stock - Currency: USD
VCYT Quote, Performance and Key Statistics
VERACYTE INC
NASDAQ:VCYT (1/31/2025, 8:00:01 PM)
After market: 46.5 +1.02 (+2.24%)45.48
-0.66 (-1.43%)
The current stock price of VCYT is 45.48 USD. In the past month the price increased by 14.85%. In the past year, price increased by 83.17%.
VCYT Latest News, Press Releases and Analysis
Exploring NASDAQ:VCYT's high growth characteristics.
Why VERACYTE INC (NASDAQ:VCYT) qualifies as a high growth stock.
Cathie Wood's Ark Invest Trims Palantir Again As Peter Thiel Co-Founded Firm's Stock Tumbles Nearly 15% In 2025
Cathie Wood-led Ark Invest sold 140,518 shares of Palantir and bought shares of Tempus AI Inc. The total value of the trades is about $9.1 million.
Veracyte Announces Third Quarter 2024 Financial Results
Veracyte to Participate in Upcoming Investor Conferences
VCYT Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 17.11 | 324.98B | ||
| AMGN | AMGEN INC | 14.85 | 153.42B | ||
| GILD | GILEAD SCIENCES INC | 21.94 | 121.14B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 905.25 | 118.90B | ||
| REGN | REGENERON PHARMACEUTICALS | 14.81 | 73.95B | ||
| ARGX | ARGENX SE - ADR | N/A | 39.17B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 34.99B | ||
| BNTX | BIONTECH SE-ADR | N/A | 29.67B | ||
| ONC | BEIGENE LTD-ADR | N/A | 23.98B | ||
| NTRA | NATERA INC | N/A | 23.36B | ||
| BIIB | BIOGEN INC | 8.81 | 20.97B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 15.86B |
Related stock screener links
About VCYT
Company Profile
Veracyte, Inc. engages in the research, development and commercialization of diagnostic products. The company is headquartered in South San Francisco, California and currently employs 815 full-time employees. The company went IPO on 2013-10-30. The firm enables clinicians with insights they need to guide and assure patients. The firm offers tests for thyroid cancer (Afirma), prostate cancer (Decipher Prostate), breast cancer (Prosigna), interstitial lung diseases (Envisia), and bladder cancer (Decipher Bladder). Its Percepta Nasal Swab test is being run in its Clinical Laboratory Improvement Amendments (CLIA) lab in support of clinical studies and its tests for kidney cancer and lymphoma are in development, the latter as a companion diagnostic. Its products consist of the Prosigna breast cancer assay, the nCounter Analysis System, related diagnostic kits, and services. In the United States, it offers laboratory developed tests (LDTs), through its CLIA labs in South San Francisco and San Diego, California, supported by its cytopathology know-how in Austin, Texas. The firm also offers whole-genome MRD platform that enable it in early cancer diagnosis and risk assessment.
Company Info
VERACYTE INC
6000 Shoreline Court, Suite 300
South San Francisco CALIFORNIA 94080 US
CEO: Bonnie H. Anderson
Employees: 815
Company Website: https://www.veracyte.com/
Investor Relations: https://investor.veracyte.com/
Phone: 16502436300
VCYT FAQ
What is the stock price of VCYT?
The current stock price of VCYT is 45.48 USD.
What is the symbol for VERACYTE INC stock?
The exchange symbol of VERACYTE INC is VCYT and it is listed on the Nasdaq exchange.
On which exchange is VCYT stock listed?
VCYT stock is listed on the Nasdaq exchange.
Is VCYT a good stock to buy?
Always make your own analysis. On these pages you can find a full technical and fundamental analysis report for VCYT, which may be a starting point for your analysis. You can also find the financials, news, analyst ratings and estimates here, which can be used to increase your understanding of VCYT.
Does VCYT stock pay dividends?
VCYT does not pay a dividend.
When does VCYT stock report earnings?
VCYT will report earnings on 2025-02-20, after the market close.
What is the Price/Earnings (PE) ratio of VCYT?
VCYT does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.15).
What is the Short Interest ratio of VCYT stock?
The outstanding short interest for VCYT is 3.63% of its float.
VCYT Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to VCYT. When comparing the yearly performance of all stocks, VCYT is one of the better performing stocks in the market, outperforming 93.63% of all stocks.
VCYT Fundamental Analysis
ChartMill assigns a fundamental rating of 5 / 10 to VCYT. VCYT has an excellent financial health rating, but there are some minor concerns on its profitability.
VCYT Financial Highlights
Over the last trailing twelve months VCYT reported a non-GAAP Earnings per Share(EPS) of -0.15. The EPS increased by 78.26% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -0.73% | ||
| ROE | -0.79% | ||
| Debt/Equity | 0 |
VCYT Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 82% to VCYT. The Buy consensus is the average rating of analysts ratings from 18 analysts.
For the next year, analysts expect an EPS growth of 133.81% and a revenue growth 24.95% for VCYT